US OptionsDetailed Quotes
AFMD250117P2500
- 1.30
- 0.000.00%
15min DelayClose Jan 3 16:00 ET
0.00High0.00Low
1.30Open1.30Pre Close0 Volume10 Open Interest2.50Strike Price0.00Turnover405.69%IV11.76%PremiumJan 17, 2025Expiry Date1.14Intrinsic Value100Multiplier13DDays to Expiry0.16Extrinsic Value100Contract SizeAmericanOptions Type-0.6607Delta0.3534Gamma1.05Leverage Ratio-0.0146Theta-0.0007Rho-0.69Eff Leverage0.0009Vega
Affimed NV Stock Discussion
Sign in to post a comment
$Affimed NV (AFMD.US)$ Watching for a possible DCB? Recent good data! Also just off 52Wk/ATL! And best of all i really like the DOJI today! Could be signaling exhaustion/trend reversal! Hmm? NFA
3
4
$Affimed NV (AFMD.US)$
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
▪️AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients
▪️AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infusion related reactions (IRRs) were the main related side effect...
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
▪️AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients
▪️AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infusion related reactions (IRRs) were the main related side effect...
2
$Affimed NV (AFMD.US)$
🤔
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Positive
High overall response rate of 86% in heavily pretreated patients
Complete response rate of 55% in patients with treatment options
Well-managed safety profile with no unexpected safety signals
Successful validation of treatment in multi-center setting
Negative
None.
🤔
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Positive
High overall response rate of 86% in heavily pretreated patients
Complete response rate of 55% in patients with treatment options
Well-managed safety profile with no unexpected safety signals
Successful validation of treatment in multi-center setting
Negative
None.
3
$Affimed NV (AFMD.US)$ Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%; Complete Response Of 55% In 22 Heavily Pretreated Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Have Exhausted All Standard Of Care Treatments
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announc...
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announc...
1
$Affimed NV (AFMD.US)$
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Sunday, 8th December at 12:00 pm
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments
The combination showed a well-managea...
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Sunday, 8th December at 12:00 pm
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments
The combination showed a well-managea...
1
$MSP Recovery (LIFW.US)$ Ticker change to MSPR Monday to consolidate services. Even with negative profit margin, of note, company had $10M settlements from property and casualty insurers and acquired Medicare claims valued $10.6B. Low float. Currently trading above 10/20 EMA suggesting short term bullishness. SI 162%, 0 shares LTB
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
51
25
6
$Affimed NV (AFMD.US)$
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Thursday, 5th December at 6:30 am
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
MANNHEIM, Germany, Dec. 05, 2024 (GLOBE NEWSWIRE) ...
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Thursday, 5th December at 6:30 am
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
MANNHEIM, Germany, Dec. 05, 2024 (GLOBE NEWSWIRE) ...
2
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
So I didn’t end up eating even half$Affimed NV (AFMD.US)$
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
$Affimed NV (AFMD.US)$ Upcoming Milestones:
-- LuminICE-203: Efficacy update of cohorts 1-4 expected to be presented at
a future scientific conference in Q4 2024.
-- AFM24-102: ORR and safety data from the EGFRwt cohort in Q4 2024.
-- AFM28-101: Data from the study is expected to be presented at a
scientific conference in Q4 2024.
-- AMF24-102: Mature PFS data from EGFRmut and EGFRwt cohorts expected to be
presented at a future conference in H1...
-- LuminICE-203: Efficacy update of cohorts 1-4 expected to be presented at
a future scientific conference in Q4 2024.
-- AFM24-102: ORR and safety data from the EGFRwt cohort in Q4 2024.
-- AFM28-101: Data from the study is expected to be presented at a
scientific conference in Q4 2024.
-- AMF24-102: Mature PFS data from EGFRmut and EGFRwt cohorts expected to be
presented at a future conference in H1...
$Immuneering (IMRX.US)$ $SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$ $S&P 500 Index (.SPX.US)$ $BioAtla (BCAB.US)$ $Gilead Sciences (GILD.US)$ $Affimed NV (AFMD.US)$ $Instil Bio (TIL.US)$ $Nkarta (NKTX.US)$
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
10
1
No comment yet
Rivera : Caming bro
Trytosaveabit OP Rivera : A bit of decent volume could send it upward nicely my friend
Rivera Trytosaveabit OP : Cheers happy holidays
Trytosaveabit OP Rivera : Thank you! A safe and wonderful Christmas to you and yours buddy🩷